Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

[1]  Mark A. Miller,et al.  Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology? , 2006, Vaccine.

[2]  Jaideep P. Sundaram,et al.  Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Rosenqvist,et al.  Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle Vaccine , 2005, Clinical Diagnostic Laboratory Immunology.

[4]  H. Käyhty,et al.  Protection by Natural Human Immunoglobulin M Antibody to Meningococcal Serogroup B Capsular Polysaccharide in the Infant Rat Protection Assay Is Independent of Complement-Mediated Bacterial Lysis , 2005, Infection and Immunity.

[5]  A. Morgan,et al.  Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children. , 2005, Vaccine.

[6]  W John Edmunds,et al.  Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. , 2005, American journal of epidemiology.

[7]  I. Aaberge,et al.  Combined Administration of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine and Conjugated Serogroup C Vaccine Indicated for Prevention of Meningococcal Disease Is Safe and Immunogenic , 2005, Clinical Diagnostic Laboratory Immunology.

[8]  K. Mulholland,et al.  From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. , 2005, Vaccine.

[9]  L. McCallum,et al.  Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. , 2005, Vaccine.

[10]  R. Rappuoli,et al.  The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. , 2005, Vaccine.

[11]  K. Mulholland,et al.  MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. , 2005, Vaccine.

[12]  B. Plikaytis,et al.  Statistical considerations for vaccine immunogenicity trials. Part 1: Introduction and bioassay design and analysis. , 2005, Vaccine.

[13]  B. Plikaytis,et al.  Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluation. , 2005, Vaccine.

[14]  A. Morgan,et al.  Persistence of Group C Anticapsular Antibodies Two to Three Years After Immunization With an Investigational Quadrivalent Neisseria meningitidis-Diphtheria Toxoid Conjugate Vaccine , 2005, The Pediatric infectious disease journal.

[15]  D. Granoff,et al.  Naturally-acquired immunity to Neisseria meningitidis group A. , 2005, Vaccine.

[16]  D. Granoff,et al.  Naturally Acquired Passive Protective Activity against Neisseria meningitidis Group C in the Absence of Serum Bactericidal Activity , 2004, Infection and Immunity.

[17]  Xu Liu,et al.  High-throughput imaging of bacterial colonies grown on filter plates with application to serum bactericidal assays. , 2004, Journal of immunological methods.

[18]  Elizabeth Miller,et al.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction , 2004, The Lancet.

[19]  D. Granoff,et al.  Protective Activity of Group C Anticapsular Antibodies Elicited in Two-Year-Olds by an Investigational Quadrivalent Neisseria meningitidis-Diphtheria Toxoid Conjugate Vaccine , 2004, The Pediatric infectious disease journal.

[20]  M. Comanducci,et al.  Protective Activity of Monoclonal Antibodies to Genome-Derived Neisserial Antigen 1870, a Neisseria meningitidis Candidate Vaccine1 , 2004, The Journal of Immunology.

[21]  G. Rougon,et al.  Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. , 2004, Vaccine.

[22]  R. Rappuoli,et al.  Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. , 2003, The Journal of infectious diseases.

[23]  N. Andrews,et al.  Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.

[24]  J. McVernon,et al.  Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. , 2003, The Journal of infectious diseases.

[25]  David Goldblatt,et al.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. , 2003, Vaccine.

[26]  A. Finn,et al.  Disparity in Functional Activity between Serum Anticapsular Antibodies Induced in Adults by Immunization with an Investigational Group A and C Neisseria meningitidis-Diphtheria Toxoid Conjugate Vaccine and by a Polysaccharide Vaccine , 2003, Infection and Immunity.

[27]  M. Ramsay,et al.  Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. , 2003, Communicable disease and public health.

[28]  A. van der Ende,et al.  Cross-Reactivity of Antibodies against PorA after Vaccination with a Meningococcal B Outer Membrane Vesicle Vaccine , 2003, Infection and Immunity.

[29]  E. Rosenqvist,et al.  Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. , 2003, Vaccine.

[30]  D. Granoff,et al.  Age-Related Disparity in Functional Activities of Human Group C Serum Anticapsular Antibodies Elicited by Meningococcal Polysaccharide Vaccine , 2003, Infection and Immunity.

[31]  I. Feavers,et al.  Assay parameters and methods of data analysis for the comparison of complement sources in the Neisseria meningitidis serogroup C serum bactericidal assay. , 2002, Biologicals : journal of the International Association of Biological Standardization.

[32]  E. Miller,et al.  Impact of meningococcal C conjugate vaccine in the UK. , 2002, Journal of medical microbiology.

[33]  K. Zerouali,et al.  Serogroups, Serotypes, Serosubtypes and Antimicrobial Susceptibility of Neisseria meningitidis Isolates in Casablanca, Morocco , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[34]  M. Maiden,et al.  Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination , 2002, The Lancet.

[35]  R. Bercion,et al.  Recent Increase in Meningitis Caused by Neisseria meningitidis Serogroups A and W135, Yaoundé, Cameroon , 2002, Emerging infectious diseases.

[36]  L. Brumana,et al.  Epidemiology of meningococcal meningitis in Angola, 1994–2000 , 2001, Epidemiology and Infection.

[37]  M. Ramsay,et al.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. , 2001, Vaccine.

[38]  M. Baker,et al.  A 10‐year serogroup B meningococcal disease epidemic in New Zealand: Descriptive epidemiology, 1991–2000 , 2001, Journal of paediatrics and child health.

[39]  T. Popović,et al.  Serosubtypes and PorA Types of Neisseria meningitidis Serogroup B Isolated in Brazil during 1997-1998: Overview and Implications for Vaccine Development , 2001, Journal of Clinical Microbiology.

[40]  A. Lucas,et al.  Imperfect memory and the development of Haemophilus influenzae type B disease. , 2001, The Pediatric infectious disease journal.

[41]  N. Andrews,et al.  Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection , 2001, Infection and Immunity.

[42]  T. Popović,et al.  Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. , 2000, The Journal of infectious diseases.

[43]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[44]  L. van Alphen,et al.  Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. , 2000, Vaccine.

[45]  J. Poolman,et al.  Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. , 1999, Vaccine.

[46]  A. Lucas,et al.  Avidity as a Determinant of the Protective Efficacy of Human Antibodies to Pneumococcal Capsular Polysaccharides , 1999, Infection and Immunity.

[47]  J. Tappero,et al.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. , 1999, JAMA.

[48]  N. Noah,et al.  Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993–6 , 1999, Epidemiology and Infection.

[49]  R. Gupta,et al.  Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. , 1998, The Journal of infectious diseases.

[50]  B. Plikaytis,et al.  Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. , 1998, The Journal of infectious diseases.

[51]  M. Baker,et al.  New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. , 1998, The Journal of infectious diseases.

[52]  P. Roholl,et al.  Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. , 1996, Vaccine.

[53]  E. Rosenqvist,et al.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine , 1995, Infection and immunity.

[54]  M. Halloran,et al.  Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. , 1995, International journal of epidemiology.

[55]  J. Boslego,et al.  Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. , 1995, Vaccine.

[56]  A. Lucas,et al.  Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain , 1995, Infection and immunity.

[57]  A. Lucas,et al.  Laboratory Correlates of Protection against Haemophilus influenzae Type b Disease , 1995, Annals of the New York Academy of Sciences.

[58]  A. Lucas,et al.  Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. , 1995, Journal of immunology.

[59]  B. Brandt,et al.  Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity , 1994, Infection and immunity.

[60]  C. Sacchi,et al.  Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy , 1994, Infection and immunity.

[61]  C. Sacchi,et al.  Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil , 1992, The Lancet.

[62]  M. Osterholm,et al.  Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. , 1992, JAMA.

[63]  E. Rosenqvist,et al.  Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. , 1991, NIPH annals.

[64]  H. Nøkleby,et al.  The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. , 1991, NIPH annals.

[65]  M. H. Terry,et al.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. , 1991, NIPH annals.

[66]  A. Halstensen,et al.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway , 1991, The Lancet.

[67]  S. Devi,et al.  Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[68]  D. Granoff,et al.  Variability in the Functional Activity of Vaccine-Induced Antibody to Haemophilus influenzae Type b , 1990, Pediatric Research.

[69]  D. Granoff,et al.  Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. , 1987, The Journal of pediatrics.

[70]  D. Bitter‐Suermann,et al.  An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. , 1987, Journal of immunology.

[71]  J. Lindon,et al.  Production of colominic acid by Pasteurella haemolytica serotype A2 organisms , 1987 .

[72]  K. G. Nickerson,et al.  A human monoclonal macroglobulin with specificity for alpha(2----8)- linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA , 1986, The Journal of experimental medicine.

[73]  M. Frosch,et al.  Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo. , 1986, Microbial pathogenesis.

[74]  R. Roy,et al.  Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. , 1985, Journal of immunology.

[75]  C. Frasch,et al.  SAFETY OF VACCINES CONTAINING MENINGOCOCCAL GROUP B POLYSACCHARIDE , 1984, The Lancet.

[76]  M. Leinonen,et al.  ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis , 1983, The Lancet.

[77]  K. Bøvre,et al.  Surface polysaccharide of Moraxella non-liquefaciens identical to Neisseria meningitidis group B capsular polysaccharide. A chemical and immunological investigation. , 1983, NIPH annals.

[78]  P. Mäkelä,et al.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. , 1983, The Journal of infectious diseases.

[79]  R. Mandrell,et al.  Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide , 1983, Infection and immunity.

[80]  C. Frasch,et al.  Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay , 1982, Infection and immunity.

[81]  C. Frasch,et al.  Rapid serogroup identification of Neisseria meningitidis by using antiserum agar: Prevalence of serotypes in a disease-free military population , 1979, Journal of clinical microbiology.

[82]  C. Cordova,et al.  TYPE-III HYPERUPOPROTEINÆMIA , 1977, The Lancet.

[83]  E. Moxon,et al.  Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1 , 1977, Infection and immunity.

[84]  J. Robbins,et al.  FREQUENCY OF E. COLI K ANTIGENS IN URINARY-TRACT INFECTIONS IN CHILDREN , 1977, The Lancet.

[85]  J. Robbins,et al.  EPIDEMIOLOGY OF ESCHERICHIA COLI K1 IN HEALTHY AND DISEASED NEWBORNS , 1975, The Lancet.

[86]  G. Mccracken,et al.  Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. , 1974, The New England journal of medicine.

[87]  D. Kasper,et al.  Immunologic response of man to group B meningococcal polysaccharide vaccines. , 1972, The Journal of infectious diseases.

[88]  M. Artenstein,et al.  Human immunity to the meningococcus. II. Development of natural immunity. , 1969 .

[89]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS I. THE ROLE OF HUMORAL ANTIBODIES , 1969 .

[90]  Saunders Kb.  [The brown adipose tissue]. , 1965, Il Policlinico. Sezione pratica.

[91]  U LJUNGQVIST,et al.  LASERS IN THE LABORATORY. , 1964, Lancet.

[92]  R. Rappuoli,et al.  Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide. , 1995, Vaccine.

[93]  P. A. van der Ley,et al.  Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. , 1995, Vaccine.

[94]  H. Ward,et al.  Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. , 1977, Scandinavian journal of infectious diseases.